Journal of Clinical and Diagnostic Research (Nov 2019)

Evaluation of Sensitivity and Resistance of Linezolid in Pre Extensively Drug Resistance Tuberculosis and Extensively Drug Resistance Tuberculosis at a Tertiary Care Hospital, Jamnagar, Gujarat, India

  • Dipali Maganbhai Gavali,
  • Binita Aring,
  • Summiya Mullan,
  • Akhlakahemad A Nathametha,
  • Abhishek B Dave

DOI
https://doi.org/10.7860/JCDR/2019/42544.13298
Journal volume & issue
Vol. 13, no. 11
pp. DC14 – DC17

Abstract

Read online

Introduction: The diseases have a high prevalence in India, accounting for one fourth of the Tuberculosis (TB) cases in the world. The situation becomes more complicated due to the rising of Human Immunodeficiency virus/AIDS pandemic, the emergence of Multidrug- Resistance (MDR) TB, Pre Extensively Drug Resistance (Pre-XDR) TB, and Extensively Drug Resistance (XDR) TB. Therefore, new anti-TB drugs are urgently needed to treat MDR-TB, Pre XDR-TB, and XDR-TB. Linezolid was the first oxazolidinone compound licensed for clinical use. Aim: To evaluate the sensitivity and resistance of linezolid in Pre XDR-TB and XDR-TB patients at a tertiary care hospital, Jamnagar, Gujarat, India. Materials and Methods: This was a prospective study conducted from May 2017 to January 2018. Total sample received were 590 MDR-TB suspected cases. All samples were proceeded for rapid detection of MDR of Mycobacterium tuberculosis by direct Drug Susceptibility Testing (DST) using Bactec MGIT 960 system. Results: Out of the total 590 samples, 468 were culture positive among this: 14 (3%) were linezolid resistance, 9 were Pre XDRTB with linezolid resistance, 03 were XDR-TB with linezolid resistance and 2 were only linezolid resistance. A total of 454 (97%) were linezolid sensitive, 143 were Pre XDR-TB with linezolid sensitive and 19 were XDR-TB with linezolid sensitive. A total of 14 (3%) were HIV infected of which 2 had Pre XDR-TB and 1 had XDR-TB. All 14 were linezolid sensitive. Conclusion: The present study showed that linezolid was found to be highly sensitive (97%) with low (3%) resistance in MDR-suspected patients. Linezolid is effective in treatment of MDR-TB, Pre XDR-TB and XDR-TB patient, but while receiving linezolid, patients should be closely monitored for signs or symptoms of bone marrow toxicity and peripheral and optic neuropathy.

Keywords